Corden Pharma vs Pfizer CentreOne: CDMO Comparison

How does Corden Pharma compare to Pfizer CentreOne for mRNA/LNP manufacturing?

Side-by-side comparison of Corden Pharma and Pfizer CentreOne on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Plankstadt, DE · Caponago, IT · Boulder, CO
Signal Score
82/100
Quality (FDA + GMP)
100/100
FDA inspections
4
— NAI / VAI / OAI
1 / 3 / 0
FDA warning letters
0
EMA GMP certificates (active)
10
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
0
Capacity
Modalities
mRNA, Oligonucleotide, Biologics
Kalamazoo, MI · McPherson, KS
Signal Score
92/100
Quality (FDA + GMP)
100/100
FDA inspections
4
— NAI / VAI / OAI
3 / 1 / 0
FDA warning letters
0
EMA GMP certificates (active)
14
MHRA GMP certificates (compliant)
3
Clinical programs (matched)
366
Capacity
Modalities
Biologics, mRNA

Key differences

  • Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
  • Pfizer CentreOne maintains 3 MHRA / UK GMP certificates; Corden Pharma does not.
  • Pfizer CentreOne appears as a manufacturing partner on more matched clinical programs (366 vs 0) — a broader sponsor book.

On a 13-modality CDMO landscape, both Corden Pharma and Pfizer CentreOne qualify as mRNA/LNP manufacturers; Pfizer CentreOne carries the higher composite Signal Score for mRNA/LNP programs in this comparison.

What to evaluate for mRNA/LNP programs

Both Corden Pharma and Pfizer CentreOne qualify as mRNA/LNP CDMOs. When choosing between them for mRNA/LNP programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.

IVT mRNA synthesis

Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost.

LNP formulation

LNP encapsulation via microfluidics determines potency and tolerability. Confirm lipid sourcing, formulation freedom-to-operate, and particle-size control.

Plasmid / starting material

mRNA needs a DNA template. Check whether the CDMO supplies GMP plasmid in-house or coordinates a plasmid CDMO — it affects timelines.

Cold chain & stability

mRNA-LNP products are temperature-sensitive. Evaluate frozen storage, fill-finish, and the stability program.

See all mRNA/LNP CDMOs ranked by Signal Score →

Frequently asked: Corden Pharma vs Pfizer CentreOne

How does Corden Pharma compare to Pfizer CentreOne for mRNA/LNP manufacturing?

On CDMO Signal's composite Signal Score, Corden Pharma is 82/100 and Pfizer CentreOne is 92/100; Corden Pharma has 4 FDA inspections on record vs 4 for Pfizer CentreOne; European coverage is 10 active EMA+MHRA certificates for Corden Pharma vs 17 for Pfizer CentreOne. Both are tracked in the CDMO Signal directory as mRNA/LNP CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.

Which has the stronger FDA inspection record, Corden Pharma or Pfizer CentreOne?

Both Corden Pharma and Pfizer CentreOne maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Corden Pharma has 4 FDA inspections on record; Pfizer CentreOne has 4.

How do Corden Pharma and Pfizer CentreOne compare on European GMP coverage?

Corden Pharma holds 10 active EMA GMP certificates and 0 MHRA / UK certificates. Pfizer CentreOne holds 14 active EMA GMP certificates and 3 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

Which is more active in clinical-stage manufacturing — Corden Pharma or Pfizer CentreOne?

Corden Pharma is matched to 0 ClinicalTrials.gov records as a manufacturing partner; Pfizer CentreOne is matched to 366. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.

Which is better for mRNA/LNP manufacturing — Corden Pharma or Pfizer CentreOne?

Both Corden Pharma and Pfizer CentreOne are tagged as mRNA/LNP CDMOs in our directory, so both are credible options for mRNA/LNP programs. The most important differentiator for mRNA/LNP selection is typically ivt mrna synthesis: Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost. Review each CDMO's profile and inspection record before shortlisting.

Evaluating Corden Pharma and Pfizer CentreOne for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.